Table 1.
A summary of the frequency of diagnosed specific delays in development in comparison with organic mercury exposure from Thimerosal-containing hepatitis B vaccine administration within the Vaccine Safety Datalink (VSD) database.
| Group examined | Number diagnosed with specific delays in development (%) | Number of individuals in the cohort | Relative risk (95% CI) | Attributable risk % (95% CI) | Population attributable risk % (95% CI) |
|---|---|---|---|---|---|
| Experiment I | |||||
| 12.5 μg Organic mercury within the first mo | 828 (4.25) | 18,637 | 1.220* (1.117–1.332) | 0.767 (0.420–1.14) | 7.64 (4.2–11.08) |
| 0 μg Organic mercury within the first mo | 1127 (3.49) | 31,198 | |||
| Experiment II | |||||
| 25 μg Organic mercury within the first 2 mo | 829 (4.25) | 18,660 | 1.214* (1.112–1.327) | 0.751 (0.403–1.10) | 7.57 (4.072–11.07) |
| 0 μg Organic mercury within first 2 mo | 1105 (3.50) | 30,444 | |||
| Experiment III | |||||
| 37.5 μg Organic mercury within the first 6 mo | 641 (4.46) | 13,725 | 2.667* (1.866–3.812) | 2.89 (2.11–3.46) | 59.62 (45.87–73.38) |
| 0 μg Organic mercury within the first 6 mo | 31 (1.67) | 1822 | |||
CI = confidence interval.
*
p < 0.001.